Key regulatory developments are impacting biotech and healthcare landscapes. The FDA announced daily publication of adverse event reports, enhancing transparency and post-market safety surveillance. The Supreme Court approved $783 million in NIH grant cuts linked to diversity, equity, and inclusion initiatives, affecting research funding dynamics. In India, the Delhi High Court ordered the blocking of Sci-Hub and related shadow libraries over copyright infringement, fueling debate on information access versus intellectual property rights. These regulatory shifts underscore evolving governance impacting biomedical research and innovation ecosystems.